



25 **Methods**

26 This project began in February 2021 and is expected to conclude by March 2022. During this time, a total  
27 of six group model-building (GMB) sessions will have been held with key stakeholders to elicit feedback  
28 that will, in turn, contribute to the development of a more robust SD model. Session participants include  
29 bystanders who witness an overdose, law enforcement personnel, first responders, pharmacists,  
30 physicians, and other health care professionals who work in at least two major metropolitan areas of  
31 Connecticut (New Haven and Hartford). Due to the restrictions imposed by the COVID-19 pandemic, the  
32 sessions are being held virtually via Zoom. The information obtained during these sessions will be  
33 integrated with a draft SD model that has already been developed by the modeling team as part of a  
34 previous CDC-funded project. Model calibration and policy simulations will then be performed to assess  
35 the impact of the current GSLs and to make recommendations for future public policy changes.

36 **Discussion**

37 An SD modeling approach enables capture of complex interrelationships among multiple health  
38 outcomes to better assess the drivers of the opioid epidemic in Connecticut. The model's simulation  
39 results are expected not only to align with current real-world data but also to recreate historical trends  
40 and infer future trends in a situationally relevant fashion. This will facilitate the work of policy makers  
41 who are devising and implementing time-sensitive changes to address opioid overdose-related deaths at  
42 the state level. Replicating our approach as described can be applied to make similar improvements in  
43 other jurisdictions.

44

45 **CONTRIBUTIONS TO THE LITERATURE**

46 - System dynamics (SD) modeling and group model-building (GMB) approaches enable the group to start  
47 with a simple concept model and apply the collective knowledge of the group to finish the session with a  
48 much more developed model that can produce impressively accurate simulation results.

49 - The model will be used to understand the impact of Connecticut's Good Samaritan Laws (GSLs), as well  
50 as their limitations, and to deduce factors to further improve public health laws to counter opioid  
51 overdose-related deaths.

52 - The approach can be applied to other jurisdictions, taking into account local conditions and existing  
53 Good Samaritan legislation.

54  
55 **KEYWORDS:** System dynamics modeling, group model building, opioid overdose deaths, opioid use  
56 disorder, Good Samaritan laws

57  
58 **BACKGROUND**

59  
60 In late 2017, after the deaths due to opioid-related overdoses had almost tripled within a decade (1),  
61 the US Department of Health and Human Services declared opioid use-related casualties to be a national  
62 public health emergency and called for immediate augmentation of interventions. Deaths resulting from  
63 opioid-related overdoses are now the leading cause of preventable human deaths in the US (2, 3). In  
64 Connecticut, drug overdose fatality rates showed a significant increase for all races combined, estimated  
65 to be 3.6 deaths per 100,000 population per year, making it an exemplar of the opioid overdose trend in  
66 the New England region of our country (4).

67  
68 The persistent increase in opioid poisoning deaths remains a national public health crisis, demanding  
69 innovative policy interventions to counter this crisis. One major intervention is the widespread  
70 distribution of naloxone, an opioid antagonist that reverses the adverse effects of opioids. The  
71 intervention has targeted people who misuse opioids and their families through expanded prescribing  
72 and community distribution (5-9). Almost all states have enacted some form of a Good Samaritan law

73 (GSL) to reduce deaths from opioid overdose. These GSLs are intended to provide legal protection  
74 against liability and arrest for bystanders who give assistance during an overdose incident by  
75 administering naloxone. In addition, they can protect first responders and individuals who prescribe or  
76 provide naloxone that is administered during an episode. Connecticut's GSL was originally passed in  
77 2011 and has been updated and expanded several times since 2014 (10, 11).

78  
79 Previous efforts to curb the opioid overdose epidemic have focused on restricting the supply of  
80 prescription narcotics used for analgesia; however, the epidemic has transitioned from being driven by  
81 pharmaceutical to non-pharmaceutical opioids. Interventions that merely restrict the supply of  
82 pharmaceuticals has proven inadequate to reduce opioid overdose related mortality and morbidity. The  
83 changing nature of the epidemic requires novel interventions based on harm reduction and demand  
84 reduction, and these are crucial now more than ever as the COVID pandemic has accelerated the  
85 incidence of opioid overdoses. Without implementation of effective public health interventions, the  
86 opioid crisis is expected to persist in the next decade due to several factors, including an expected  
87 increase in the number of individuals using illicit opioids, easy availability of illicit opioids, and the  
88 increase in lethality of these illicit opioids due to the highly potent synthetic opioid fentanyl that now  
89 dominates the US supply (12, 13).

90  
91 Responding to the opioid epidemic is just one of many public health issues that present complex  
92 challenges requiring a systems approach to assess the different components of health and prevention  
93 systems. Novel approaches are needed to explore component interactions and devise policy options  
94 that consist of the most effective and efficient arrangements of multiple resources available within a  
95 system. One such approach is system dynamics (SD) modeling which, according to Homer and Hirsch,

96 involves “an interlocking set of differential and algebraic equations that are devised from a broad  
97 spectrum of measured and experiential data” (14).

98

99 We are employing an SD approach to assess the numerous factors that impact the influence of the GSLs  
100 in Connecticut and will incorporate measurement of multiple factors and their concurrent variance to  
101 determine this influence. The statewide modeling will focus on the following three primary health  
102 outcomes: (1) emergency department visits for drug misuse and overdose, (2) behavioral changes of  
103 bystanders, and (3) overdose deaths. We believe that this model will prove to be superior to the use of  
104 more traditional methods such as surveys, participant interviews, and state level comparisons of policy  
105 modifications in assessing the effectiveness of the GSL. By providing insights that cannot be obtained  
106 through these other means of analysis, we expect that the modeling outputs will provide a more  
107 structured understanding of the effectiveness of the GSLs by explaining feedback loops and endogenous  
108 sources of system behavior (15) .

109

110 The Centers for Disease Control’s (CDC) Prescription Drug Overdose (PDO) Prevention for States (PFS)  
111 program was designed to promote and evaluate state-level interventions for “preventing drug overuse,  
112 misuse, abuse, and overdose;” and this policy evaluation represents this group’s attempt to address the  
113 goal articulated by the CDC. In response to recommendations from the National Academies of Sciences,  
114 Engineering and Medicine (NASEM), the Federal Drug and Food administration (FDA) has now accepted  
115 an SD modeling approach as their nationwide approach to assess the impact of GSLs that have been  
116 implemented throughout the country (16-19)

117

118 We developed this protocol paper as means of describing SD modeling as a novel way of assessing the  
119 impact of public health interventions and developing and testing effective public health policies that  
120 address complex policy problems.

121

## 122 **METHODS/DESIGN**

123

### 124 **Study Setting**

125 Connecticut has witnessed a steady increase in total overdose deaths among residents, from 357 deaths  
126 in 2012 to 1,374 deaths in 2020, an increase of almost 285% (20). Almost half of these deaths occurred  
127 at a residence. In 2016, the state ranked 11<sup>th</sup> in terms of opioid overdose related deaths in the country  
128 with 27.4 deaths per every 100,000 people (21). Many of Connecticut's neighboring states are also  
129 among the top 10 states for their rates of overdose deaths. This includes New Hampshire (39  
130 deaths/100,000 people), Massachusetts (33 deaths/100,000 people), Rhode Island (30.8 deaths/100,000  
131 people), and Maine (28.7 deaths/100,000 people)(22). Regardless of gender, race, and age, the opioid  
132 epidemic continues to worsen in Connecticut (22). Males have higher rates of overdose deaths than  
133 females. These demographic trends are consistent throughout most of the nation. The average age of  
134 death varies significantly, with whites dying at a younger age than blacks and Hispanics each year in  
135 Connecticut (20). Most overdose deaths in CT involved illicit drugs, such as fentanyl, heroin, and cocaine,  
136 rather than prescription drugs (4). Heroin was the most common substance leading to opioid-related  
137 deaths among CT residents from 2012-2017 (22, 23). More recently, fentanyl has predominated and  
138 now is involved in 85-90% of all accidental drug poisonings (20).

139

140 The passage of the CT GSL in 2011 was intended to reduce the reluctance to administer naloxone by  
141 providing immunity, by statute, from criminal prosecution to the bystander who responded to an

142 overdose even if law enforcement found evidence of illicit drug use or presence at the scene. It  
143 expanded the statute that already allowed licensed health care professionals to administer an opioid  
144 antagonist to a drug user without fear of liability for civil damages or criminal prosecution. The scope of  
145 the GSL was expanded in 2012 to offer protection from civil penalties to prescribing practitioners,  
146 pharmacists, law enforcement agencies, emergency medical service providers, government agencies,  
147 community health organizations and other entities that distribute naloxone for use in responding to  
148 opioid overdoses. It was expanded again in 2014 to protect against liability for civil damages or criminal  
149 prosecution for the possession of drugs or related paraphernalia to any person who administered an  
150 opioid antagonist during a suspected overdose. A related statute passed in 2015 that allowed  
151 pharmacists to sell naloxone to anyone requesting it by creating a statewide standing order, in effect  
152 turning a prescription medication into one available over the counter (11).

153

#### 154 **Conceptual framework**

155 Group model-building (GMB) is a form of participatory SD modeling with which we are capturing the  
156 knowledge and perceptions of stakeholders and domain experts. These will be analyzed and integrated  
157 to assess the effectiveness and impact of the GSLs on bystander behavior in reducing opioid-related  
158 deaths in Connecticut. The purpose of a GMB approach is twofold – to use participants’ understanding  
159 of a complex problem to reach common ground when designing policy innovations and to gain support  
160 from participants for implementation of model-based policy recommendations (24-26). We facilitate the  
161 GMB sessions using scripts that have been developed, revised, and validated by various SD expert  
162 modelers through a collaborative effort. The scripts are documented and made accessible on the  
163 Scriptapedia platform to make GMB in SD more science than art (27-29). The GMB approach engages  
164 stakeholders in a process that yields compelling, graphical outputs that inform both challenges of and  
165 solutions to complex systems problems. During the workshop, participants are oriented to systems

166 thinking and modeling and use the causal-loop diagramming (CLD) approach to describe  
167 interdependencies and sketch feedback structures.  
168  
169 SD modeling and GMB have recently been applied to implementation science in complex public health  
170 problems. For example, SD has been applied to improving developmental-behavioural screening and  
171 detection of related disorders in primary care settings (30). SD has also been a useful tool for  
172 understanding the complexity and dynamics around the adaptation and implementation of financial  
173 policies to increase health insurance in Mexico and reduce financial inequities (31). Also, participatory  
174 SD modeling using the GMB approach has been used for improving evidence-based practice for PTSD  
175 patients in the VA (32, 33). Another study has used SD modeling to study the long-term consequences of  
176 formal guidelines around mammography screening and how these are implemented, interpreted, and  
177 acted upon by various stakeholders (34).

178  
179 There remains a gap in adopting SD and participatory modeling approaches for real-time public policy  
180 analysis and assessing the impact of implementing identified policy changes at the state level. In  
181 facilitating the GMB sessions for this project that evaluates the GSLs, we are engaging key stakeholders  
182 to introduce perspectives from a broad range of expertise and experiences such that the conceptual  
183 model, with its system structures and feedback loops underlying the opioid crisis in Connecticut, has the  
184 potential for identifying policy levers for improving system outcomes.

## 185 186 **Study design**

187 Our study sets out to measure multiple factors and their simultaneous variance to determine the  
188 effectiveness of the GSLs in Connecticut. Model calibration will be used to make estimates for the  
189 parameter values that were not readily available in literature. A maximum likelihood estimation

190 approach will be used to create simulations which align best with real-world data, replicating historical  
191 trends and creating estimations for the future. To accomplish these aims, we have planned a four-part  
192 SD modeling approach. First, we have established a baseline data framework from publicly available  
193 data and created a preliminary model to develop questions to better understand how the multiple  
194 factors interact. Second, the questions are then posed to stakeholders during the GMB for directed data  
195 collection on the nature of the interactions. Finally, we will interpret the data to refine the SD model and  
196 assess if the refined model has improved predictive value.

197

### 198 ***Preparing for GMB***

199

200 Baseline data to calibrate the model are obtained from several sources. Data on nonfatal opioid-  
201 involved overdoses come from emergency medical reporting and the Connecticut Hospital Association  
202 (CHIME) discharge records. Data on fatal opioid-involved overdoses come from the CT Office of the Chief  
203 Medical Examiner. Data on illicit drug use and related arrests come from several sources compiled by  
204 Substance Abuse and Mental Health Services Administration (SAMHSA) reports from 2015 to 2020. Data  
205 on the rate of opioid prescriptions will be retrieved from the CDC report on U.S. state prescribing rates.  
206 Initial information on knowledge of the GSL and fear of calling 911 to report an overdose come from a  
207 study conducted by the Connecticut Department of Public Health (CT DPH) and Central Connecticut  
208 State University (CCSU) and a High Intensity Drug Trafficking Area's (HIDTA) Heroin Response Strategy  
209 project (35, 36). Once the baseline data had been compiled, they were used to build a preliminary SD  
210 model that identified putative interactions between events that occur to individuals within opioid using  
211 populations. The interactions were also used to formulate questions for the GMB sessions that are  
212 incorporated in scripts that allow all GMB sessions to cover the same issues (28).

213

214 ***Conducting Group Model Building Sessions***

215

216 In practice, each GMB session is two hours long and conducted by trained meeting *facilitators*,  
217 *modelers*, and *recorders*. The *lead facilitator* initiates the meeting, provides a brief introduction to the  
218 project, the *modeling team*, and *the participants*, and reviews the project's goals and intention.


219 Following this introduction, *the participants* are divided into small groups led by *facilitators* who guide  
220 *the participants* through scripts to facilitate the discussions around defining key factors. The *participants*  
221 then construct, based on their insider knowledge, behavior-over-time graph (BOTG) diagrams that focus  
222 on trends central to the problem definition and that serve to refine the modeling process (25).

223 Participants have 15 minutes to draw the graphs with prompting from *facilitators* if needed to highlight  
224 graphically their identification of a problem related to the opioid epidemic and its expected trajectory  
225 over time. Throughout the session, the *recorder* is entering a verbal account of the session into a  
226 Microsoft Word document to identify recurrent themes and key insights. The *facilitator* then reviews the  
227 graphs to form clusters and themes.

228

229 The *modeler* uses the graphs to identify a few key variables named by participants, as well as the causal  
230 links between variables to begin forming a causal loop diagram (CLD). A CLD is a directed graph that  
231 depicts how different variables in a system are interrelated. The CLDs consist of a set of variables and  
232 positive and negative causal links. Causal links represent a relation between the two variables in the  
233 form of cause and effect. Relations between variables form an abstract diagram that consists of few  
234 loops, which can depict complicated interactions about a particular problem or issue. As shown in the  
235 accompanying diagram (Figure 1), two distinct kinds of causal loops exist. *Reinforcing loops* produce  
236 exponential increase or decrease. Reinforcing loops are identifiable by an *even* number of negative  
237 causal links in them. *Balancing loops* counter change in an attempt to bring things to a stable state and

238 keep them there and consist of an *odd* number of negative causal links. As an example, a reinforcing  
239 loop describes greater availability of Narcan due to increasing acceptability of Narcan after lives are  
240 saved because of its administration (indicated by R1 in Figure 1), hence reducing overdose mortality;  
241 while in a balancing loop, an increase in the number of overdose incidents leads to more overdose  
242 fatalities and, initially, to a reduced number of people with opioid use disorder. Throughout the  
243 sessions, we are continuing to make note of these interrelationships to focus on possible interventions  
244 and modifications to devise feasible and acceptable policy changes that might contribute to our  
245 continued efforts to curb the opioid use crisis in Connecticut



246  
247 **Figure 1:** R1 depicts a reinforcing loop as Narcan use leads to lives saved, ultimately leading to more  
248 acceptance of Narcan use; whereas, B1 depicts a balancing loop that shows that overdose deaths  
249 initially lead to a reduction in the number of people with opioid use disorder.

250  
251 As more complicated CLDs emerge from the GMB, they will still contain just a few basic elements: the  
252 variables, the links between them, the signs on the links (which show how the variables are  
253 interconnected), delays, and the sign of the loop. By representing a problem or issue from a causal  
254 perspective, both modelers and participants become more aware of the structural forces that produce

255 puzzling behavior. The resulting diagrams also provide a visual representation that can be used to  
256 communicate that understanding with others.

257  
258 The *facilitator* concludes the session by asking the teams to consider insights they gained from the  
259 exercise and build their own CLDs, explaining factors driving overdose deaths by adding other variables  
260 and drawing arrows connecting them to the existing loops. During this step, each small group has the  
261 opportunity to draw attention to more important loops and comment on the relative influence of one  
262 loop on the other loops in the diagram. By using CLDs to create stories about complex issues, the group  
263 of stakeholders can make more explicit the modelers' understanding of the interrelationships within a  
264 system's structure. To ensure that as much information as possible is gleaned from these exercises, the  
265 *modeling team* engages in a reflection session led by the *debriefers* immediately following the session.

266  
267 For this project, six GMB sessions will be conducted in Connecticut over a 15-month period that ends in  
268 March 2022. While the initial plan was to focus on participants from just two parts of the state, the  
269 ongoing COVID-19 pandemic forced the GMB sessions to occur virtually and, thereby, facilitated broader  
270 statewide representation. Over the course of the study, the sessions are enabling the modeling team to  
271 capture, understand, and portray the complex interrelationships among several key health outcome  
272 measures that are impacted by the opioid epidemic in Connecticut. These outcomes include ED visits  
273 due to overdose, behavioral changes of bystanders, changes in perception of the risk of drug use,  
274 awareness of harm reduction policies, and overdose deaths. Additionally, the sessions have helped the  
275 project team to acquire a deeper understanding of the interrelationships among key stakeholders. To  
276 maximize understanding of the efficacy of current public health laws, participants are being selected  
277 from key stakeholder groups, including pharmacists, other healthcare providers, emergency medical  
278 service clinicians, law enforcement personnel, individuals who have experienced or witnessed an

279 overdose, family members of individuals who have experienced overdose, fire-fighting personnel, and  
280 other first responders. Participants are chosen carefully to provide adequate representation of the  
281 stakeholder groups that play a key role in responding to the opioid emergency. A particular emphasis  
282 has been made to include bystanders who directly benefit from the GSL, law enforcement agents who  
283 have to abide by the current laws which may differ from previous practices, and healthcare  
284 professionals and pharmacists who benefit from the protection in amendments added after 2011. The  
285 sessions have engaged participants in exercises of narrative elicitation, computerized causal loop  
286 diagramming of the underlying problems, and construction of behavior over time graphs. Stakeholder  
287 participation exercises and scripts are designed to focus attention and elicit information regarding the  
288 implementation and effectiveness of Good Samaritan Laws, with a specific focus on encouraging  
289 bystander intervention during an opioid overdose event. But participants are also encouraged to  
290 generate CLDs that identify the factors that, in their experience, influence the willingness of bystanders  
291 to act.

292  
293 Existing data narratives presented in the form of a CLD serve as the means of obtaining input and to  
294 prime the group discussion. With help from participants and the behavior-over-time graphs that they  
295 produce, the variables and the identified relationships in the CLD are updated throughout the sessions  
296 and confirmed with the participants to minimize misinterpretation. Input from each session is  
297 incorporated to enhance the next session with new information to confirm or modify the relationship.  
298 Throughout the sessions, the *recorder* continues to make notes of these relationships and possible  
299 interventions and modifications to help improve the SD model by devising feasible and acceptable policy  
300 changes that might contribute to efforts to curb the opioid use crisis in Connecticut.

301

302 Immediately following each session, the *facilitators*, in collaboration with the *recorders*, analyze how the  
303 GMB session improved participant understanding of systems thinking. The team also identifies  
304 additional information and participant insights that can be used to improve the specificity and sensitivity  
305 of the preliminary SD model, in addition to studying how each GMB session participant perceived the  
306 usefulness of the session for understanding the policy's intent and effect. The modeling team  
307 administers a GMB knowledge assessment tool to capture the level of subject knowledge of each  
308 participant using a structured set of questions (33). This allows modelers to weigh the CLDs based on  
309 their interpretation of the level of knowledge participants have brought to the CLD exercises.

310  
311 At the time this manuscript was developed, three sessions had been completed. These initial sessions  
312 involved the two main activities described above: constructing behavior-over-time graphs and  
313 contributing to causal loop diagramming. Each activity was initially performed by sub-groups and  
314 concluded with the full group engaging in discussion. For the BOTG activity, we asked participant to  
315 answer the following question graphically: "What are the facilitators and barriers that impact the  
316 effectiveness of the Good Samaritan Laws on distributing naloxone and reducing opioid-related deaths  
317 in Connecticut?" In some cases, some prompting was needed to help initiate the process. The  
318 participants were then asked to rank their graphs over time with the most important/favorite factors as  
319 first and the least important/least favorite factors as last. They were asked to either display their graphs  
320 on their camera using the Zoom application or to draw the graph on the white board tab of the  
321 software. They were then asked to describe briefly what they drew to engage in discussion. In the next  
322 activity, the participants were shown a basic CLD and engaged in forming additional loops to expand  
323 upon the relationships between various factors.

324 From the sessions that we have conducted thus far, we have learned that longer sessions  
325 (approximately 2 hours) with fewer participants (5-10 participants) in each session allow for more

326 engaging and thought-provoking sessions that seem to elicit more detailed feedback than sessions with  
327 more participants. For the subsequent three sessions that are to follow, we plan to build upon the data  
328 that has been collected in the first three sessions. We are working to derive main take-away lessons –  
329 persistent themes, opportunities to intervene, barriers to implementing potentially effective  
330 interventions – from the first three sessions and present them in CLDs to participants to engage in  
331 discussion regarding policy planning. The sessions will involve review of balancing and reinforcing loops  
332 and a review of potential policy changes.

333

### 334 ***Analysis plan***

335

336 The results of the all six modeling workshops and their follow-up assessments will then be integrated to  
337 refine the preliminary SD model that had been developed by the modeling team as part of a previous  
338 CDC-funded project to understand how laws and policies can be more effectively implemented to  
339 control the epidemic (37). We will be using tools and notation from established systems science analytic  
340 methods to help us organize the feedback that we receive during these sessions (38). These tools will  
341 allow the team to move the focus from a linear cause-and-effect paradigm to a model that includes  
342 feedback loops and interlocking causes and effects. Additionally, the analysis of the information  
343 collected during the sessions will help the project team acquire a deeper understanding of the  
344 interrelationships among key stakeholders. This understanding is key to developing actionable  
345 interventions that have both a high likelihood of reducing opioid overdose mortality and being  
346 acceptable and implementable by a broad swath of stakeholders and the affected population.

347 The team will develop policy improvement recommendations integrating the information obtained from  
348 the SD modeling exercises performed during GMB sessions and GMB post-session knowledge  
349 assessments using computerized SD model simulations with time varying elements. The model will

350 incorporate available state agency data including the number of EMS episodes and ED visits for opioid  
351 drug overdose, the number of opioid-involved overdose deaths, and use of treatment services for opioid  
352 use disorder. Data from the GMB sessions will help put bounds on unknowns such as the number of  
353 people misusing prescription medications and street drugs, changes in drug markets and drug testing for  
354 the presence of fentanyl, the behavioral changes of bystanders, and the number of police officers and  
355 members of the public who have GSL knowledge. The output will be an upgraded SD model. The model  
356 will then be used to construct “what-if” analyses to determine and rank in priority the constituent parts  
357 of the system and identify the policy innovations that are likely to result in the largest change in  
358 outcome measured as a reduction in opioid overdose deaths.

359

## 360 **DISCUSSION**

361

362 SD modeling enables us to capture and analyze the complex interrelationships that exist between  
363 multiple public health practices that ultimately impact the opioid epidemic in Connecticut. This  
364 modeling approach allows researchers to investigate the delayed and long-term impacts of policy  
365 changes such as the GSLs by facilitating construction of a simulation framework. By effectively  
366 replicating historical trends, SD modeling estimates future effectiveness of interventions without  
367 requiring extensive involvement of study participants or the need for costly pilot studies prior to  
368 widespread implementation of policy changes.

369

370 In our current effort, we have focused on GSLs that were passed and progressively expanded in  
371 Connecticut beginning 10 years ago. SD modeling can prove beneficial as an analytic tool to assess the  
372 expected impact of modifications which, otherwise, might not demonstrate observable outcomes for  
373 several years, as policy changes often take time before widespread adoption. Modeling can also help to

374 integrate data sets by producing data-driven simulations that can account for missing or incomplete  
375 variables where the basic direction of causality between important variables is thought to be  
376 understood. The GMB sessions focus attention on directionality. Additionally, this type of modeling can  
377 be especially helpful when the definition of the system of interest (in our case, the state of Connecticut)  
378 is clear.

379  
380 We employed the SD modelling approach to assess the effectiveness of the current CT GSL; however, we  
381 intend to use the model to assess other strategies to combat the opioid crisis. Our model structure and  
382 feedback loops are very relevant to the opioid epidemic and, thus, can be easily calibrated to apply to  
383 different locations for the same purpose. A key benefit of the GMB sessions is that participating  
384 stakeholders come to understand the model and have bought into the process of using models to  
385 predict the impact of policy changes. Thus, one of the biggest advantages of using the SD model is  
386 allowing public health decision makers in Connecticut to appreciate, employ, and even update the  
387 current SD model and anticipate the impact of new or evolving policies that may come their way. An  
388 additional benefit of the project, as a whole, is the development of an approach that can be applied  
389 elsewhere even if circumstances specific to Connecticut may differ. The GMB sessions are central to the  
390 process of making a general approach that can be attuned to local conditions.

391  
392 **Limitations and future recommendations:**

393  
394 Due to limitations imposed by the COVID-19 pandemic, sessions are conducted virtually via Zoom. This  
395 initially created technical difficulties for some of our participants and interrupted optimal interactions  
396 between the *facilitators*, *modeler*, and *participants*. However, this challenge led the project team to

397 develop a set of best practices for virtual GMB facilitation that will likely become increasingly useful as  
398 virtual research becomes a more mainstream method for this type of evaluation.

399

#### 400 **LIST OF ABBREVIATIONS**

401 SD – Systems dynamic modelling

402 GMB – Group-based model-building

403 CLD – Causal Loop Diagrams

404 GSL – good Samaritan law

405

#### 406 **DECLARATION**

407 • Ethics approval and consent to participate

408 This project is a collaborative work of researchers from Yale University and City University of  
409 New York (CUNY). The project was approved by Yale University IRB on 10/6/20 (Yale IRB  
410 #2000028908) and CUNY IRB on 12/30/20 (CUNY IRB number: HRPP #2020-0958).

411 • Consent for publication

412 Not applicable

413 • Availability of data and materials

414 Not applicable

415 • Competing interests

416 Not applicable

417 • Funding

418 This project was funded under contract to the Connecticut Department of Public Health (DPH)  
419 on behalf of the Centers for Disease Control and Prevention (CDC): Prescription Drug Overdose  
420 Prevention for States (CDC Grant Number: 1U17CE002720-02) and was supported by Grant or

421 Cooperative Agreement number 6NU17CE925011-03-02, funded by the Centers for Disease  
422 Control and Prevention. Its contents are solely the responsibility of the authors and do not  
423 necessarily represent the official views of the Centers for Disease Control and Prevention or the  
424 Department of Health and Human Services. The contents presented do not necessarily reflect CT  
425 DPH or CDC policy.

426 • Authors' contributions

427 SSA, NS, RH, GD, RH drafted the manuscript and contributed to the design of the study. CV and  
428 KL collaborated with the modeling team to help develop the project's specifications and provide  
429 guidance on Connecticut Department of Public Health policies for this public health initiative. All  
430 authors read and approved the final manuscript.

431 • Acknowledgements

432 We would like to acknowledge Susan Logan from the Connecticut Department of Public Health  
433 for her support of the project.

434 • Authors' information (optional)

435

436 **REFERENCES**

437

438 1. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—  
439 United States, 2013–2017. *Morbidity and Mortality Weekly Report*. 2019;67(5152):1419.

440 2. Watson DP, Ray B, Robison L, Huynh P, Sights E, Brucker K, et al. Lay responder naloxone access  
441 and Good Samaritan law compliance: postcard survey results from 20 Indiana counties. *Harm reduction*  
442 *journal*. 2018;15(1):18.

- 443 3. Chen Q, Larochelle MR, Weaver DT, Lietz AP, Mueller PP, Mercaldo S, et al. Prevention of  
444 prescription opioid misuse and projected overdose deaths in the United States. *JAMA network open*.  
445 2019;2(2):e187621-e.
- 446 4. Wu ZH, Yong Q, Walker JM, Grady JJ, Laurencin CT. Fentanyl, Heroin, and Cocaine Overdose  
447 Fatalities are Shifting to the Black Community: An Analysis of the State of Connecticut. *J Racial Ethn*  
448 *Health Disparities*. 2021.
- 449 5. Albert S, Brason FW, 2nd, Sanford CK, Dasgupta N, Graham J, Lovette B. Project Lazarus:  
450 community-based overdose prevention in rural North Carolina. *Pain Med*. 2011;12 Suppl 2:S77-85.
- 451 6. Bennett AS, Elliott L. Naloxone's role in the national opioid crisis-past struggles, current efforts,  
452 and future opportunities. *Transl Res*. 2021;234:43-57.
- 453 7. Doe-Simkins M, Walley AY, Epstein A, Moyer P. Saved by the nose: bystander-administered  
454 intranasal naloxone hydrochloride for opioid overdose. *Am J Public Health*. 2009;99(5):788-91.
- 455 8. Keane C, Egan JE, Hawk M. Effects of naloxone distribution to likely bystanders: Results of an  
456 agent-based model. *Int J Drug Policy*. 2018;55:61-9.
- 457 9. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, et al. Naloxone distribution and  
458 cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot  
459 intervention study. *J Urban Health*. 2005;82(2):303-11.
- 460 10. DMHAS. Opioid Overdose Prevention/Naloxone (Narcan) Initiative. Connecticut Department of  
461 Mental Health & Addiction Services; 2019.
- 462 11. The Good Samaritan Law in CT. Available from: [https://www.drugfreect.org/resources/ct-good-](https://www.drugfreect.org/resources/ct-good-samaritan-law/)  
463 [samaritan-law/](https://www.drugfreect.org/resources/ct-good-samaritan-law/).
- 464 12. Cicero TJ, Ellis MS, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. *Addict*  
465 *Behav*. 2017;74:63-6.

- 466 13. Wilson N KM, Seth P, Smith H IV, Davis NL. . Drug and Opioid-Involved Overdose Deaths —  
467 United States, 2017–2018. MMWR Morb Mortal Wkly Rep 2020;69:290–297. DOI.
- 468 14. Homer JB, Hirsch GB. System dynamics modeling for public health: background and  
469 opportunities. American journal of public health. 2006;96(3):452-8.
- 470 15. Atkinson J-A, Wells R, Page A, Dominello A, Haines M, Wilson A. Applications of system dynamics  
471 modelling to support health policy. Public Health Res Pract. 2015;25(3):e2531531.
- 472 16. Naumann RB, Austin AE, Sheble L, Lich KH. System dynamics applications to injury and violence  
473 prevention: a systematic review. Curr Epidemiol Rep. 2019;6:248-62.
- 474 17. Wakeland W, Nielsen A, Geissert P. Dynamic model of nonmedical opioid use trajectories and  
475 potential policy interventions. Am J Drug Alcohol Abuse. 2015;41(6):508-18.
- 476 18. Wakeland W, Schmidt T, Gilson AM, Haddox JD, Webster LR. System dynamics modeling as a  
477 potentially useful tool in analyzing mitigation strategies to reduce overdose deaths associated with  
478 pharmaceutical opioid treatment of chronic pain. Pain Med. 2011;12 Suppl 2:S49-58.
- 479 19. FDA Opioid Systems Modeling Effort. Available from: [https://www.fda.gov/drugs/information-](https://www.fda.gov/drugs/information-drug-class/fda-opioid-systems-modeling-effort)  
480 [drug-class/fda-opioid-systems-modeling-effort](https://www.fda.gov/drugs/information-drug-class/fda-opioid-systems-modeling-effort).
- 481 20. Opioids and Prescription Drug Overdose Prevention. Connecticut Department of Public Health.  
482 Unintentional drug overdose deaths in Connecticut: a fact sheet – 2020. 2020.
- 483 21. Opioids and Prescription Drug Overdose Prevention. Available from:  
484 [https://portal.ct.gov/dph/Health-Education-Management--Surveillance/The-Office-of-Injury-](https://portal.ct.gov/dph/Health-Education-Management--Surveillance/The-Office-of-Injury-Prevention/Opioids-and-Prescription-Drug-Overdose-Prevention-Program)  
485 [Prevention/Opioids-and-Prescription-Drug-Overdose-Prevention-Program](https://portal.ct.gov/dph/Health-Education-Management--Surveillance/The-Office-of-Injury-Prevention/Opioids-and-Prescription-Drug-Overdose-Prevention-Program).
- 486 22. Ankrah J. Connecticut's Opioid Epidemic: A Glimpse of the Past Five Years. DataHaven, 2018.
- 487 23. 2012-2017 Accidental Drug-Related Deaths. Connecticut Office of the Chief Medical Examiner :  
488 <https://data.ct.gov/Health-and-Human-Services/Accidental-Drug-Related-Deaths-2012-2017/ecj5-r2i9>.
- 489 24. JA V. Group model-building: tackling messy problems. System Dynamics Review. 1999.

- 490 25. Andersen DF, Richardson GP. Scripts for group model building. *System Dynamics Review*.  
491 1997;13:107-29.
- 492 26. Andersen DF, Richardson GP, Vennix JAM. Group model building: adding more science to the  
493 craft. *System Dynamics Review*. 1997;13(2):187-201.
- 494 27. Hovmand PS. *Group Model Building and Community-Based System Dynamics Process*.  
495 *Community Based System Dynamics*. New York, NY: Springer New York; 2014. p. 17-30.
- 496 28. Hovmand PS, Andersen DF, Rouwette E, Richardson GP, Rux K, Calhoun A. Group Model-Building  
497 'Scripts' as a Collaborative Planning Tool. *Systems Research and Behavioral Science*. 2012;29(2):179-93.
- 498 29. WikiBooks. Available from: <https://en.wikibooks.org/wiki/Scriptapedia>.
- 499 30. Sheldrick RC, Breuer DJ, Hassan R, Chan K, Polk DE, Benneyan J. A system dynamics model of  
500 clinical decision thresholds for the detection of developmental-behavioral disorders. *Implementation*  
501 *Science*. 2016;11(1):1-14.
- 502 31. Nigenda G, González-Robledo LM, Juárez-Ramírez C, Adam T. Understanding the dynamics of  
503 the Seguro Popular de Salud policy implementation in Mexico from a complex adaptive systems  
504 perspective. *Implementation Science*. 2015;11(1):1-12.
- 505 32. Lounsbury D, Kibbe D, Rollins J, Zimmerman L, editors. *From blank page to local optimization:  
506 participatory systems modeling to improve local evidence based practice implementation*.  
507 *Implementation Science*; 2020: BMC Campus, 4 Crinan St, London N1 9XW, England.
- 508 33. Zimmerman L, Lounsbury DW, Rosen CS, Kimerling R, Trafton JA, Lindley SE. Participatory  
509 *System Dynamics Modeling: Increasing Stakeholder Engagement and Precision to Improve*  
510 *Implementation Planning in Systems*. *Administration and Policy in Mental Health and Mental Health*  
511 *Services Research*. 2016;43(6):834-49.
- 512 34. Karanfil O, Sterman JD. A dynamic model for health screening: misperceptions, feedback and  
513 long term trends in screening mammography. *Implementation Science*. 2015;10(1):A50.

- 514 35. HIDTA. Heroin Response Strategy - 911 Good Samaritan Law Cornerstone Project - Preliminary  
515 State Report Connecticut: High Intensity Drug Trafficking Areas (HIDTA) Program - White House Office of  
516 National Drug Control Policy; 2019.
- 517 36. Hawk KF, Doernberg M, D’Onofrio G, Heimer R, Diaz-Matos LF, Jenkins M, et al. Knowledge of  
518 Connecticut’s Good Samaritan Law Among Connecticut Residents Who Have Witnessed an Overdose.  
519 2019.
- 520 37. Sabounchi NS, Heckmann R, D’Onofrio G, Walker J, Heimer R. Assessing the Impact of the Good  
521 Samaritan Law in the State of Connecticut: A System Dynamics Approach. Health Research Policy and  
522 Systems. Accepted December 2021.
- 523 38. Sterman J. System Dynamics: systems thinking and modeling for a complex world  
524 2002.  
525

